Compare · ABT vs HROW
ABT vs HROW
Side-by-side comparison of Abbott Laboratories (ABT) and Harrow Inc. (HROW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and HROW operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $157.63B, about 127.8x HROW ($1.23B).
- Over the past year, ABT is down 32.2% and HROW is up 9.6% - HROW leads by 41.8 points.
- ABT has been more active in the news (6 items in the past 4 weeks vs 5 for HROW).
- ABT has more recent analyst coverage (25 ratings vs 10 for HROW).
- Company
- Abbott Laboratories
- Harrow Inc.
- Price
- $90.44-0.69%
- $33.11-0.21%
- Market cap
- $157.63B
- $1.23B
- 1M return
- +4.00%
- -15.23%
- 1Y return
- -32.20%
- +9.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 10
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Harrow Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest HROW
- Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Harrow to Present at William Blair's 46th Annual Growth Stock Conference
- Director Silvernail Lauren P bought $31,000 worth of shares (1,000 units at $31.00) (SEC Form 4)
- Director Graves Adrienne L bought $31,070 worth of shares (1,000 units at $31.07) (SEC Form 4)
- SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Shojaei Amir
- CHIEF EXECUTIVE OFFICER Baum Mark L bought $302,000 worth of shares (10,000 units at $30.20), increasing direct ownership by 0.33% to 2,996,130 units (SEC Form 4)
- PRESIDENT AND CFO Boll Andrew R. bought $104,650 worth of shares (3,500 units at $29.90), increasing direct ownership by 0.43% to 814,679 units (SEC Form 4)
- SEC Form 10-Q filed by Harrow Inc.
- Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Harrow Announces First Quarter 2026 Financial Results